论文部分内容阅读
目的探讨苯磺酸氨氯地平联合贝那普利对维持性血液透析患者左心室重构的影响。方法收集2012年3月-2014年4月来我院就诊的维持性血液透析患者160例,在常规透析药物治疗的基础上给予苯磺酸氨氯地平联合贝那普利治疗。分别于治疗时和治疗后0.5年检测其血清氨基末端脑钠肽(NT-pro BNP)和超敏C-反应蛋白(hs-CRP)水平,同时采用超声心动图检测判其左室重塑变化。结果治疗后0.5年血清NT-pro BNP和hs-CRP水平均低于治疗时,差异均有统计学意义(P<0.05)。经治疗0.5年后患者LVEDD、LVDS、IVST、LVM和LVMI水平低于治疗时,差异均有统计学意义(P<0.05)。其余指标治疗前后变化较小,差异均无统计学意义(P>0.05)。结论苯磺酸氨氯地平联合贝那普利可改善维持性血液透析患者左心室重构,效果较好,值得临床推广应用。
Objective To investigate the effect of amlodipine besylate combined with benazepril on left ventricular remodeling in maintenance hemodialysis patients. Methods 160 cases of maintenance hemodialysis patients who visited our hospital from March 2012 to April 2014 were collected and treated with amlodipine besylate and benazepril on the basis of routine dialysis drug therapy. Serum levels of serum NT-proBNP and hs-CRP were measured at the time of treatment and 0.5 years after treatment, respectively. Meanwhile, the change of left ventricular remodeling was determined by echocardiography . Results The levels of serum NT-pro BNP and hs-CRP at 0.5 year after treatment were both lower than those at the treatment, the difference was statistically significant (P <0.05). After treatment for 0.5 years, the LVEDD, LVDS, IVST, LVM and LVMI levels were lower than those in the treatment group (P <0.05). The other indexes changed little before and after treatment, the difference was not statistically significant (P> 0.05). Conclusion Combined use of amlodipine besylate and benazepril can improve left ventricular remodeling in patients undergoing maintenance hemodialysis, which is worthy of clinical application.